16
Apr

Commercializing the First Treatment for Spinal Cord Injury 

IE Business School is glad to invite you and the members of your network to join the fifth in a series of videoconferences titled Biotechnology Management Today, on Thursday, April 22nd at 16:00 (Madrid local time).

Speaker: Frank Reynolds Chairman of the Board and CEO at InVivo Therapeutics Corporation

 Content: 

The theme of Mr. Reynolds’ presentation will be the management of a life sciences company focused on bringing a treatment option for spinal cord injury patients to market. Mr. Reynolds  will present on the science of spinal cord injury, the tenants behind InVivo Therapeutics’ technology, and the research conducted to date, including the results of several successful studies. He will also speak about the company’s business model, the product development timeline, regulatory pathway, and financial aspects of the business.   

Bio:

Frank Reynolds co-founded InVivo Therapeutics Corporation with 2008 Millennium Laureate Robert S. Langer, Director of MIT’s Langer Lab to develop the first treatment for traumatic spinal cord injury. InVivo’s novel neurological science and technologies were designed and developed at Massachusetts Institute of Technology and Harvard Medical School. Mr. Reynolds leads the scientific and business teams at InVivo Therapeutics Corporation to commercialize a biomaterial-based platform technology that can be utilized to treat every type of spinal cord injury.  Prior to founding InVivo Therapeutics in 2005, Mr. Reynolds was Director, Global Business Development for Siemens Corporation where he was responsible for new business revenue in 132 countries.

Please confirm your attendance by sending an e-mail to mbmconferences@ie.edu . Upon confirmation we will send you the link to the open videoconference. 

If you are unable to join this conference but wish to be kept informed of future open conferences, please let us know. 

Master in Biotechnology Management Team

Comments

Sorry, the comment form is closed at this time.

We use both our own and third-party cookies to enhance our services and to offer you the content that most suits your preferences by analysing your browsing habits. Your continued use of the site means that you accept these cookies. You may change your settings and obtain more information here. Accept